for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nanobiotix SA

NANOB.PA

Latest Trade

6.27EUR

Change

0.06(+0.89%)

Volume

86,687

Today's Range

6.17

 - 

6.35

52 Week Range

6.06

 - 

16.19

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
6.21
Open
6.23
Volume
86,687
3M AVG Volume
1.32
Today's High
6.35
Today's Low
6.17
52 Week High
16.19
52 Week Low
6.06
Shares Out (MIL)
22.35
Market Cap (MIL)
137.86
Forward P/E
-3.49
Dividend (Yield %)
--

Next Event

Nanobiotix SA Annual Shareholders Meeting

Latest Developments

More

Nanobiotix Announces Phase I Study Results On NBTXR3

Nanobiotix H1 Net Loss Widens To 23.9 Million Euros

Nanobiotix Q2 Revenue Drops To 31,900 Euros

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Nanobiotix SA

Nanobiotix SA is a France-based oncology focused nanomedicine company. It is engaged in developing nanoparticle technology. It develops new tools for cancer which utilize a physical mode of action at the cellular level of the cancer cell. This disruptive approach may reshape future treatment opportunities. The Company's NanoXray technology comprises three products having the potential to cause a paradigm shift in cancer therapy. Specifically, NanoXray products may overcome the current limitations of standard of care in local therapy. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Industry

Biotechnology & Drugs

Contact Info

60 rue de Wattignies

+33.1.40260470

https://www.nanobiotix.com

Executive Leadership

Laurent Condomine

Independent Chairman of the Supervisory Board

Laurent Levy

Chairman of the Management Board and Chief Executive Officer

Philippe Mauberna

Member of the Management Board, Chief Financial Officer,

Alain Dostie

Chief Operating Officer

Edwina Baskin-Bey

Member of the Management Board, Medical Director

Key Stats

1.14 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-1.430

2017

-1.500

2018

-1.547

2019(E)

-1.778
Price To Earnings (TTM)
--
Price To Sales (TTM)
1,729.77
Price To Book (MRQ)
6.69
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
212.59
LT Debt To Equity (MRQ)
201.82
Return on Investment (TTM)
-83.93
Return on Equity (TTM)
-69.89

Latest News

Latest News

BRIEF-Nanobiotix Did Not Generate Any Revenue In Q1

* ANNOUNCED ON TUESDAY IT DID NOT GENERATE ANY REVENUE FOR Q1 2018, AS IT HAD EXPECTED

BRIEF-Nanobiotix Partners With Weill Cornell Medicine

* PARTNERSHIP ON PRE-CLINICAL STUDIES TO EVALUATE NBTXR3 IMPACT ON CGAS-STING PATHWAY IN MAMMARY CANCERS

BRIEF-Nanobiotix FY Net Loss Widens to 26.1 Million Euros

* TOTAL REVENUE IN 2017 AMOUNTS TO EUR 3.7M VERSUS. EUR 5.4M IN 2016

BRIEF-Nanobiotix Presents Data From Phase I/II Liver Cancers Trial Of NBTXR3

* NANOBIOTIX PRESENTS FIRST PROMISING DATA FROM PHASE I/II LIVER CANCERS TRIAL OF NBTXR3 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY GASTROINTESTINAL ANNUAL MEETING

BRIEF-Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers

* NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS

BRIEF-Nanobiotix: FDA Approves First Immuno-Oncology Trial

* NANOBIOTIX : FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL

BRIEF-Nanobiotix Q3 revenue down at 33.0 million euros

* Q3 REVENUE EUR 33.0 MILLION VERSUS EUR 58.6 MILLION YEAR AGO Source text: http://bit.ly/2zKWYHz Further company coverage: (Gdynia Newsroom)

BRIEF-Nanobiotix completes new share issue for about 27.2 million euros

* NANOBIOTIX SUCCESSFULLY COMPLETES APPROXIMATELY EUR 27.2 MILLION PLACEMENT OF NEW SHARES

BRIEF-Nanobiotix completes patient inclusion for phase II/III trial of NBTXR3

* NANOBIOTIX COMPLETES PATIENT INCLUSION FOR PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA

BRIEF-Nanobiotix to conduct its first clinical trial with NBTXR3 in the U.S.

* PLANS TO CONDUCT ITS FIRST CLINICAL TRIAL WITH NBTXR3 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN U.S.

BRIEF-Nanobiotix H1 net loss widens to 12.2 million euros

* H1 NET LOSS EUR 12.2 MILLION VERSUS LOSS OF EUR 10.2 MILLION YEAR AGO

BRIEF-Nanobiotix Q2 revenue down at 58,645 euros

* H1 RENTAL REVENUE EUR 91.5 MLN VS EUR 91.4 MLN YR AGO Source text: http://bit.ly/2tJ0z7p Further company coverage: (Gdynia Newsroom)

BRIEF-Nanobiotix presents new data on NBTXR3

* ANNOUNCED ON THURSDAY PRESENTATION OF NEW TRANSLATIONAL DATA AT ASTRO, NCI AND SITC'S IMMUNOTHERAPY WORKSHOP

BRIEF-Nanobiotix says Phase I/II head and nack cancer trial shows promising results

* NANOBIOTIX : PROMISING DATA FROM PHASE I/II HEAD AND NECK CANCER TRIAL WITH NBTXR3 PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY'S ANNUAL MEETING

BRIEF-Nanobiotix announces first positive data of NBTXR3 in immuno-oncology

* NANOBIOTIX ANNOUNCES FIRST POSITIVE HUMAN DATA SHOWING THAT NBTXR3 COULD BECOME A BACKBONE IN IMMUNO-ONCOLOGY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Nanobiotix SA announces no revenue booked during Q1 2017

* HAS NO Q1 REVENUE IN 2017 VS Q1 EUR 45,847 YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Nanobiotix FY net loss widens to 21.9 million euros

* FY total revenue 5.4 million euros ($5.88 million) versus 4.0 million euros year ago

BRIEF-Nanobiotix completes approximately 25.1 million euros private placement of new shares

* Completes approximately 25.1 million euros ($26.70 million) private placement of new shares

BRIEF-Nanobiotix launches capital increase

* Nanobiotix launches capital increase by means of an accelerated bookbuild offering

BRIEF-Nanobiotix announced presentation of NBTXR3 preclinical studies demonstrating antitumor efficacy of NBTXR3

* Studies demonstrating antitumor efficacy of NBTXR3 in five different in vivo human cancer models

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up